Introduction {#section5-2040622319879602}
============

National Health Insurance in Taiwan is well known worldwide and has a high coverage rate.^[@bibr1-2040622319879602]^ Therefore, the average years of survival among Taiwanese individuals is increasing under this affordable and well-developed health care system. When people live longer, they frequently have a higher chance of having chronic diseases. In current clinical practice, under the assumption of one guideline that is applied to all adults,^[@bibr2-2040622319879602]^ multiple medications are more likely to be prescribed for multimorbid patients, because each guideline might recommend an average of three medications.^[@bibr3-2040622319879602],[@bibr4-2040622319879602]^ As the number of medications increases, the incidence of adverse drug reactions (ADRs) and drug--drug and drug--disease interactions increases significantly.^[@bibr5-2040622319879602]^ ADRs are associated with falls, geriatric syndrome, higher rates of hospitalization, and mortality.^[@bibr6-2040622319879602],[@bibr7-2040622319879602]^ In previous studies, some ADRs were regarded as preventable when medications with high risks of ADRs can be avoided before they are prescribed.

Drugs with a risk of ADRs outweighing clinical benefits, uncertain therapeutic effects, or with safer alternatives for older people are defined as ''potentially inappropriate medications' (PIMs).^[@bibr8-2040622319879602]^ Under this concept, explicit criteria are established to discourage the use of PIMs in older people. The first established PIM criteria was the Beers criteria in the United States in 1991.^[@bibr8-2040622319879602]^ The initial arrangement of this list was not a system-oriented arrangement, and the PIMs were selected from locally available drugs and regarded as inappropriate according to experts opinions. However, it has been updated^[@bibr9-2040622319879602]^ and applied to clinical practice and many clinical studies to find the associations between PIMs and outcomes over the past two decades.^[@bibr10-2040622319879602]^ However, the prescription preference of physicians and the drug market varies in different regions of the world. Therefore, regional PIM criteria are preferred, and they have also been developed in many countries including Germany,^[@bibr11-2040622319879602]^ France,^[@bibr12-2040622319879602]^ Ireland,^[@bibr13-2040622319879602]^ Norway,^[@bibr14-2040622319879602]^ Italy,^[@bibr15-2040622319879602]^ Thailand,^[@bibr16-2040622319879602]^ Japan,^[@bibr17-2040622319879602]^ and Canada.^[@bibr18-2040622319879602]^

Establishing a new set of criteria is time-consuming, particularly during the literature review process, and relatively few studies have enrolled older people with multiple comorbidities in clinical trials. Since the publication of the Beers criteria in 1991, most regional PIM criteria have been derived from expert's opinions using the modified Delphi method.^[@bibr19-2040622319879602]^ Based on regionally available drugs, the consensus among regional experts was obtained using the modified Delphi method. The PIM-Taiwan criteria have been established and have proven their applicability in several cross-sectional studies among older Taiwanese adults.^[@bibr20-2040622319879602][@bibr21-2040622319879602]--[@bibr22-2040622319879602]^ In comparison with the Beers criteria and PRISCUS criteria, PIM-Taiwan can detect a similar number of PIMs across different populations in Taiwan. PIM users had higher health resource utilization and higher costs of medications^[@bibr20-2040622319879602],[@bibr21-2040622319879602]^ than non-PIM users.

As technology advanced and new results from clinical studies emerged, many new medications were developed after 2010, and some of the statements in the PIM criteria were considered irrelevant or inaccurate. In addition, some older drugs are not available in the market. Therefore, the aim of this study was to establish a new version of the PIM-Taiwan criteria using a two-round modified Delphi method, and intraclass correlations were used to investigate the correlation and agreement among experts' opinions.

Methods {#section6-2040622319879602}
=======

Establishment of a preliminary list {#section7-2040622319879602}
-----------------------------------

The initial literature review was conducted on PubMed from studies published from 1 January 2011 to 1 January 2017. We selected this time limit for literature inclusion because our PIM-Taiwan criteria were published in 2012. Because we could not include some sets of criteria that were published 1 year before the PIM-Taiwan publication year (2012), we searched for studies dated after 2011. The search included the terms (potentially inappropriate medication list \[MeSH\] OR inappropriate prescribing \[All Fields\] OR inappropriate prescribing/classification \[All Fields\] OR inappropriate prescription \[All Fields\]). The MeSH term 'potentially inappropriate medications' was introduced in 2016. Prior to this time, the term 'inappropriate prescribing' was used.

As an initial step for the development of PIM criteria in Taiwan, we identified nine sets^[@bibr9-2040622319879602],[@bibr11-2040622319879602],[@bibr13-2040622319879602],[@bibr15-2040622319879602],[@bibr17-2040622319879602],[@bibr23-2040622319879602][@bibr24-2040622319879602][@bibr25-2040622319879602]--[@bibr26-2040622319879602]^ of explicit criteria published in the English language. After criteria were omitted that were developed based on other published criteria, we selected four sets of criteria to develop a preliminary list ([Figure 1](#fig1-2040622319879602){ref-type="fig"}). A research team was convened, including three geriatricians, one psychiatrist, and two clinical pharmacists, to create a list of preliminary PIMs from the four published criteria. For the preliminary list of PIMs that should be generally avoided, the Beers criteria, Japan criteria, and FORTA criteria were used as references. For PIMs with respect to comorbidity, the Beers criteria, Japan criteria, and Screening Tool of Older Persons' Prescriptions (STOPP) criteria were used as references. Medications/medication classes that appeared in at least two out of three sets of the criteria were selected and reviewed by the research team. The research team reviewed the concerns regarding these PIMs and approved a preliminary list that consisted of 169 individual drugs and 9 drugs with combinations to be generally avoided and 9 statements for drug--disease interactions.

![Flow diagram of the systemic literature review and selection of explicit criteria.](10.1177_2040622319879602-fig1){#fig1-2040622319879602}

The availability of medications in Taiwan listed in the preliminary PIM list was confirmed using the medication database from the National Health Insurance Administration. We identified generic names and the Anatomical Therapeutic Chemical (ATC) Classification System code for each medication. When a set of medication classes, rather than an individual medication, was considered potentially inappropriate, we identified all available medications in Taiwan belonging to this set of medication classes. For anticholinergic drugs, we reviewed the literature to define the strong anticholinergic drugs that were given a score of at least two on the 'Anticholinergic Risk Scale'.^[@bibr9-2040622319879602],[@bibr27-2040622319879602]^

Modified Delphi method {#section8-2040622319879602}
----------------------

A group of 24 experts from different specialties (geriatricians, neurologists, psychiatrists, cardiologists, pulmonologists, gastroenterologists, urologists, and clinical pharmacists) was invited to develop a consensus using the modified Delphi methods from the preliminary PIM list. Briefly, this method is a form of communication among these experts with a structured questionnaire to reach a consensus decision. All nongeriatric experts were selected because they are experienced and skilled in the principles of prescribing for older people and have reputations in their specialties in Taiwan. Hard copies of the questionnaire were mailed to all of the experts. A brief introduction of the modified Delphi method and scoring methodology was also given. Then, the experts were asked to rank each statement according to its degree of inappropriateness using a 5 point Likert scale that ranged from 5 points (strongly agree) to 1 point (strongly disagree). In addition, the experts could add suggestions for PIMs that were not listed originally or remove PIMs in the preliminary list. The first round of the questionnaires was scored by each expert by October 2017. PIMs with a mean Likert scale ⩾3.5 were scored again by November 2017. During round two, we also gave the mean score for each statement, and all experts could find the opinion of other experts in round one. We also welcomed the suggestions of new statements or alternative therapies from the experts. The PIM list was finalized from medications/medication classes with mean Likert scale scores ⩾3.5 after two rounds of rating. We welcomed the suggestions of new statements or alternative therapies from the experts, and the alternative therapies or suggestions for each PIM to be generally avoided were finalized by four clinical pharmacists. Finally, the research team confirmed that all PIMs were available in Taiwan, and that all of the concerns and alternative therapies/suggestions were optimized.

Theory and calculation {#section9-2040622319879602}
----------------------

The resulting data generated by the hard copies of the survey were imported into Microsoft Excel (Microsoft Office 2013) for analysis. Descriptive statistics were used to measure the consistency of each measurement. The intraclass correlation coefficient (ICC) estimates and their 95% confidence intervals were calculated using Stata statistical package version 13 (Stata, College Station, TX, USA) based on a mean-rating (*k* = 24), consistency, and a two-way mixed-effect model.

According to the 'Human Subjects Research Act' in Taiwan, this study did not involve obtaining, investigating, analyzing, or using human specimens or an individual person's biological behavior, physiological, psychological, genetic, or medical information. Therefore, this study was not human subject research. In the legislation of the Research Ethics Committee of National Taiwan University Hospital, the study did not need ethical approval as it was not human subject research. The objectives of the Delphi method were presented to all experts, their agreement and availability to participate were obtained (consisted of replying positively by email to the invitation sent by the research team). The information that this study generated was used for consensual quality criteria only and can be publicly accessible and there is no reasonable expectation of privacy.

Results {#section10-2040622319879602}
=======

The preliminary list consisted of 169 individual drugs and 9 drugs with combinations, for example, 'promethazine, combinations' (ATC code R05FA02) to be avoided generally and 9 statements for drug--disease interaction. A total of 29 individual drugs were not available in 2018. PIMs in the first round (*n* = 9) with mean Likert scale scores \<3.5 were not entered into the second round. The response rate of the hard copies of the questionnaire was 100% in two rounds of the Delphi method. After two rounds of the modified Delphi method, the final PIM-Taiwan criteria included 131 individual drugs, 9 drugs with combinations to be avoided generally ([Table 1](#table1-2040622319879602){ref-type="table"}), and 9 statements for drug--disease interaction. When an entire medication class was considered to be PIMs, all individual drugs available in the class are listed in [Table 1](#table1-2040622319879602){ref-type="table"}. We designated the symbol marker^†^ for drugs that were already listed in the 2012 PIM-Taiwan criteria. Alternative therapies or suggestions for PIMs were created to prevent the general use of PIMs. When there was no optimal alternative medication for certain PIMs, we recommended other nonpharmacological therapies. For example, antipsychotics for behavioral problems of dementia or delirium should be avoided among older adults because the mortality rate is higher for antipsychotic users. Therefore, nonpharmacological options (e.g. behavioral interventions, such as psychosocial interventions, reality orientation, and physical activity) are suggested first for the behavioral problems of dementia or delirium.^[@bibr28-2040622319879602]^ Otherwise, PIMs should be used only for a short duration for those with appropriate indications. [Table 2](#table2-2040622319879602){ref-type="table"} summarizes drug--disease interactions, which included individual medications or medication classes that should be avoided in patients with corresponding chronic diseases. The entire medication class should be considered inappropriate if patients have a corresponding chronic disease. [Table 3](#table3-2040622319879602){ref-type="table"} lists 131 individual drugs in 10 medication classes overall. The ATC codes, medication/medication classes, and reasons for inclusion are provided. The statements and drugs have been removed since the 2012 version of PIM-Taiwan were enumerated ([Table 4](#table4-2040622319879602){ref-type="table"}). The entire medication class of muscle relaxants was removed from PIM-Taiwan.

###### 

2018 version for potentially inappropriate medication use in persons aged ⩾65 years of age (PIM-Taiwan) independent of diagnoses or chronic diseases.

![](10.1177_2040622319879602-table1)

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Category                  Subtype                                                              Drugs                                                                                       ATC code   Concern                                                                                                                                                                                         Alternatives/suggestions
  ------------------------- -------------------------------------------------------------------- ------------------------------------------------------------------------------------------- ---------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cardiovascular system     Alderostone antagonists                                              Spironolactone                                                                              C03DA01    Risk of hyperkalemia.                                                                                                                                                                           Use other diuretics or regularly monitor serum potassium.

                            Antiarrhythmic                                                       Amiodarone                                                                                  C01BD01    With greater toxicities than other antiarrhythmics used in atrial fibrillation.                                                                                                                 Use other rhythm control medications for atrial fibrillation.

                            Central alpha blockers                                               Clonidine^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^                            C02AC01    High risk of adverse central nervous system effects; may cause orthostatic hypotension and bradycardia.                                                                                         Use other first-line antihypertensive as suggested by guidelines.

                            Digitalis glycoside                                                  Digoxin \>0.125 mg/d^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^                 C01AA05    Should not be used for atrial fibrillation because it may be associated with higher mortality. When it has been used for heart failure, higher dosages were associated with higher mortality.   Use medications for rhythm control, except amiodarone for atrial fibrillation.

                            Peripheral alpha-1 blockers                                          Prazosin                                                                                    C02CA01    High risk of orthostatic hypotension; not first-line treatment for hypertension.                                                                                                                Use other first-line antihypertensive as suggested by guidelines.

                                                                                                 Doxazosin                                                                                   C02CA04                                                                                                                                                                                                    

                                                                                                 Terazosin                                                                                   G04CA03                                                                                                                                                                                                    

  Endocrine system          Androgens                                                            Methyltestosterone                                                                          G03BA02    Potentially increased risk of cardiac problems; contraindicated in men with malignancy of prostate.                                                                                             Avoid use unless absolutely indicated.

                                                                                                 Testosterone                                                                                G03BA03                                                                                                                                                                                                    

                            Estrogens (including combination)                                    Estradiol                                                                                   G03CA03    Carcinogenic potential (breast and endometrium); lack of cardiovascular or cognitive protective effects in older women.                                                                         Vaginal estrogens for treatment of vaginal dryness are safe, but those with history of breast cancer are advised to discuss the risk-benefits ratio of low-dose vaginal estrogen therapy with their health provider.

                                                                                                 Estriol                                                                                     G03CA04                                                                                                                                                                                                    

                                                                                                 Estrone                                                                                     G03CA07                                                                                                                                                                                                    

                                                                                                 Estradiol, combinations                                                                     G03CA53                                                                                                                                                                                                    

                                                                                                 Conjugated estrogens                                                                        G03CA57                                                                                                                                                                                                    

                                                                                                 Norethisterone and estrogen                                                                 G03FA01                                                                                                                                                                                                    

                                                                                                 Hydroxyprogesterone and estrogen                                                            G03FA02                                                                                                                                                                                                    

                                                                                                 Progesterone and estrogen                                                                   G03FA04                                                                                                                                                                                                    

                                                                                                 Norgestrel and estrogen                                                                     G03FA10                                                                                                                                                                                                    

                                                                                                 Medroxyprogesterone and estrogen                                                            G03FA12                                                                                                                                                                                                    

                            Sulfonylureas, long-duration                                         Glyburide (glibenclamide)                                                                   A10BB01    Long half-life; can cause prolonged hypoglycemia.                                                                                                                                               Use other oral hypoglycemic agents.

                                                                                                 Chlorpropamide^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^                       A10BB02                                                                                                                                                                                                    

                            Thiazolidinediones                                                   Pioglitazone                                                                                A10BG03    Can lead to osteoporosis and fractures in women; exacerbation of heart failure.                                                                                                                 Use other oral hypoglycemic agents when patients have heart failure or osteoporosis.

  Gastrointestinal system   H2-receptor antagonists                                              Cimetidine^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^                           A02BA01    Central nervous system adverse effects with potential to induce or worsen delirium.                                                                                                             Proton-pump inhibitors (avoid \>8 weeks unless for special circumstances).

                                                                                                 Ranitidine                                                                                  A02BA02                                                                                                                                                                                                    

                                                                                                 Famotidine                                                                                  A02BA03                                                                                                                                                                                                    

                                                                                                 Nizatidine                                                                                  A02BA04                                                                                                                                                                                                    

                            Propulsives                                                          Metoclopramide                                                                              A03FA01    Can cause extrapyramidal effects.                                                                                                                                                               Domperidone, mosapride.

                            Synthetic anticholinergic agents in combination with psycholeptics   Clidinium and chlordiazepoxide^[\*](#table-fn1-2040622319879602){ref-type="table-fn"}^      A03CA02    High anticholinergic effects that may lead to risk of confusion, urinary retention, constipation, dry mouth, etc.                                                                               Avoid long-term use.

  Genitourinary system      Drugs for urinary frequency and incontinence                         Oxybutynin^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^\                          G04BD04\   High anticholinergic effects that may lead to risk of confusion, urinary retention, constipation, dry mouth, etc.                                                                               Use other drugs with less anticholinergic activity.

                                                                                                 Tolterodine                                                                                 G04BD07c                                                                                                                                                                                                   

  Nervous system\           Antidepressants, selective serotonin reuptake inhibitors (SSRIs)     Paroxetine                                                                                  N06AB05    High anticholinergic effects that may lead to sedation, urinary retention, and orthostatic hypotension. Increased risk of skin and mucosa bleeding and hyponatremia.                            Use other antidepressants, except TCAs.
  \                                                                                                                                                                                                                                                                                                                                                                                                     
  \                                                                                                                                                                                                                                                                                                                                                                                                     

                            Antidepressants, in combination                                      Melitracen^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^ and psycholeptics         N06CA02    High anticholinergic effects that may lead to sedation, urinary retention, and orthostatic hypotension.                                                                                         Use other antidepressants, except paroxetine.

                            Antidepressants, tetracyclic                                         Maprotiline                                                                                 N06AA21                                                                                                                                                                                                    

                            Antidepressants, tricyclic                                           Imipramine^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^                           N06AA02                                                                                                                                                                                                    

                                                                                                 Clomipramine^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^                         N06AA04                                                                                                                                                                                                    

                                                                                                 Amitriptyline^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^                        N06AA09                                                                                                                                                                                                    

                                                                                                 Doxepin^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^                              N06AA12                                                                                                                                                                                                    

                            Antiparkinsonian agents                                              Trihexyphenidyl (benzhexol)                                                                 N04AA01    High anticholinergic effects that may lead to confusion, urinary retention, constipation, dry mouth, etc.                                                                                       Use other antiparkinsonian drugs.

                                                                                                 Biperiden                                                                                   N04AA02                                                                                                                                                                                                    

                            Antipsychotics, first-generation (conventional)                      Chlorpromazine^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^                       N05AA01    Increased risk of cerebrovascular accident.                                                                                                                                                     Avoid antipsychotics for behavioral problems of dementia or delirium unless nonpharmacological options (e.g. behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others.

                                                                                                 Levomepromazine^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^\                     N05AA02\                                                                                                                                                                                                   

                                                                                                 Fluphenazine\                                                                               N05AB02\                                                                                                                                                                                                   

                                                                                                 Perphenazine\                                                                               N05AB03\                                                                                                                                                                                                   

                                                                                                 Trifluoperazine\                                                                            N05AB06\                                                                                                                                                                                                   

                                                                                                 Thioridazine^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^                         N05AC02                                                                                                                                                                                                    

                                                                                                 Haloperidol                                                                                 N05AD01                                                                                                                                                                                                    

                                                                                                 Flupentixol\                                                                                N05AF01\                                                                                                                                                                                                   

                                                                                                 Chlorprothixene                                                                             N05AF03                                                                                                                                                                                                    

                                                                                                 Pimozide\                                                                                   N05AG02\                                                                                                                                                                                                   

                                                                                                 Loxapine^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^                             N05AH01                                                                                                                                                                                                    

                                                                                                 Sulpiride                                                                                   N05AL01                                                                                                                                                                                                    

                            Antipsychotics, second-generation (atypical)                         Ziprasidone\                                                                                N05AE04\   Increased risk of cerebrovascular accident.                                                                                                                                                     Avoid antipsychotics for behavioral problems of dementia or delirium unless nonpharmacological options (e.g. behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others.

                                                                                                 Lurasidone\                                                                                 N05AE05\                                                                                                                                                                                                   

                                                                                                 Clozapine^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^                            N05AH02                                                                                                                                                                                                    

                                                                                                 Olanzapine\                                                                                 N05AH03\   (stroke) and greater rate of cognitive decline and mortality in persons with dementia.                                                                                                          

                                                                                                 Amisulpride\                                                                                N05AL05\                                                                                                                                                                                                   

                                                                                                 Risperidone\                                                                                N05AX08\                                                                                                                                                                                                   

                                                                                                 Zotepine\                                                                                   N05AX11\                                                                                                                                                                                                   

                                                                                                 Aripiprazole                                                                                N05AX12                                                                                                                                                                                                    

                                                                                                 Paliperidone                                                                                N05AX13                                                                                                                                                                                                    

                            Benzodiazepines                                                      Clonazepam^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^                           N03AE01    Increased risk of cognitive impairment, confusion, falls, fractures, and motor vehicle accidents.                                                                                               Avoid as possible; low-dose and short-term use as needed.

                                                                                                 Diazepam^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^                             N03BA01                                                                                                                                                                                                    

                                                                                                 Medazepam                                                                                   N03BA03                                                                                                                                                                                                    

                                                                                                 Oxazepam                                                                                    N05BA04                                                                                                                                                                                                    

                                                                                                 Lorazepam                                                                                   N05BA06                                                                                                                                                                                                    

                                                                                                 Bromazepam                                                                                  N05BA08                                                                                                                                                                                                    

                                                                                                 Clobazam^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^                             N05BA09    Increased risk of cognitive impairment, confusion, falls, fractures, and motor vehicle accidents.                                                                                               

                                                                                                 Prazepam                                                                                    N05BA11                                                                                                                                                                                                    

                                                                                                 Alprazolam                                                                                  N05BA12                                                                                                                                                                                                    

                                                                                                 Nordazepam^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^                           N05BA16                                                                                                                                                                                                    

                                                                                                 Fludiazepam^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^                          N05BA17                                                                                                                                                                                                    

                                                                                                 Oxazolam^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^                             N05BA                                                                                                                                                                                                      

                                                                                                 Flurazepam^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^                           N05CD01                                                                                                                                                                                                    

                                                                                                 Nitrazepam^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^                           N05CD02                                                                                                                                                                                                    

                                                                                                 Flunitrazepam^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^                        N05CD03                                                                                                                                                                                                    

                                                                                                 Estazolam                                                                                   N05CD04                                                                                                                                                                                                    

                                                                                                 Triazolam^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^                            N05CD05                                                                                                                                                                                                    

                                                                                                 Midazolam                                                                                   N05CD08                                                                                                                                                                                                    

                                                                                                 Brotizolam                                                                                  N05CD09                                                                                                                                                                                                    

                            Nonbenzodiazepine hypnotics                                          Zopiclone                                                                                   N025CF01                                                                                                                                                                                                   

                                                                                                 Zolpidem                                                                                    N025CF02                                                                                                                                                                                                   

                                                                                                 Zaleplon                                                                                    N025CF03                                                                                                                                                                                                   

                                                                                                 Eszopiclone                                                                                 N025CF04                                                                                                                                                                                                   

  Pain medications          Non-COX-2 selective nonsteroidal anti-inflammatory drugs (NSAIDs)    Indomethacin^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^                         M01AB01    Increased risk of gastrointestinal bleeding or peptic ulcer disease; concurrent use of proton-pump inhibitor or misoprostol reduces but does not fully prevent the risk.\                       Use acetaminophen or COX-2 selective NSAIDs; avoid long-term use.
                                                                                                                                                                                                        Increased risk of acute kidney injury.                                                                                                                                                          

                                                                                                 Sulindac                                                                                    M01AB02                                                                                                                                                                                                    

                                                                                                 Tolmetin                                                                                    M01AB03                                                                                                                                                                                                    

                                                                                                 Diclofenac                                                                                  M01AB05                                                                                                                                                                                                    

                                                                                                 Alclofenac                                                                                  M01AB06                                                                                                                                                                                                    

                                                                                                 Etodolac                                                                                    M01AB08                                                                                                                                                                                                    

                                                                                                 Acemetacin                                                                                  M01AB11                                                                                                                                                                                                    

                                                                                                 Ketorolac^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^                            M01AB15                                                                                                                                                                                                    

                                                                                                 Aceclofenac                                                                                 M01AB16                                                                                                                                                                                                    

                                                                                                 Piroxicam^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^                            M01AC01                                                                                                                                                                                                    

                                                                                                 Tenoxicam                                                                                   M01AC02                                                                                                                                                                                                    

                                                                                                 Meloxicam                                                                                   M01AC06                                                                                                                                                                                                    

                                                                                                 Ibuprofen                                                                                   M01AE01                                                                                                                                                                                                    

                                                                                                 Naproxen                                                                                    M01AE02                                                                                                                                                                                                    

                                                                                                 Ketoprofen                                                                                  M01AE03                                                                                                                                                                                                    

                                                                                                 Fenoprofen                                                                                  M01AE04                                                                                                                                                                                                    

                                                                                                 Fenbufen                                                                                    M01AE05                                                                                                                                                                                                    

                                                                                                 Flurbiprofen                                                                                M01AE09                                                                                                                                                                                                    

                                                                                                 Tiaprofenic acid                                                                            M01AE11                                                                                                                                                                                                    

                                                                                                 Mefenamic acid                                                                              M01AG01                                                                                                                                                                                                    

                                                                                                 Flufenamic acid                                                                             M01AG03                                                                                                                                                                                                    

                                                                                                 Meclofenamic acid                                                                           M01AG04                                                                                                                                                                                                    

                                                                                                 Nabumetone                                                                                  M01AX01                                                                                                                                                                                                    

                                                                                                 Niflumic acid                                                                               M01AX02                                                                                                                                                                                                    

                                                                                                 Benzydamine                                                                                 M01AX07                                                                                                                                                                                                    

                                                                                                 Nimesulide                                                                                  M01AX17                                                                                                                                                                                                    

  Respiratory system        First-generation antihistamines                                      Brompheniramine, combinations                                                               R01BA52    High anticholinergic effects that may lead to confusion, urinary retention, constipation, dry mouth, etc.                                                                                       Second-generation antihistamine.

                                                                                                 Triprolidine, combinations                                                                  R01BA02                                                                                                                                                                                                    

                                                                                                 Promethazine, combinations                                                                  R05FA02                                                                                                                                                                                                    

                                                                                                 Dexchlorpheniramine, combinations                                                           R05X                                                                                                                                                                                                       

                                                                                                 Diphenhydramine^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^                      R06AA02                                                                                                                                                                                                    

                                                                                                 Dimenhydrinate                                                                              R06AA02                                                                                                                                                                                                    

                                                                                                 Clemastine^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^                           R06AA04                                                                                                                                                                                                    

                                                                                                 Diphenylpyraline^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^                     R06AA07                                                                                                                                                                                                    

                                                                                                 Carbinoxamine^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^                        R06AA08                                                                                                                                                                                                    

                                                                                                 Doxylamine^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^                           R06AA09                                                                                                                                                                                                    

                                                                                                 Diphenhydramine, combinations                                                               R06AA52                                                                                                                                                                                                    

                                                                                                 Diphenylpyraline, combinations                                                              R06AA57                                                                                                                                                                                                    

                                                                                                 Brompheniramine^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^                      R06AB01                                                                                                                                                                                                    

                                                                                                 Dexchlorpheniramine^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^                  R06AB02                                                                                                                                                                                                    

                                                                                                 Chlorpheniramine^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^                     R06AB04                                                                                                                                                                                                    

                                                                                                 Promethazine^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^                         R06AD02                                                                                                                                                                                                    

                                                                                                 Mequitazine^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^                          R06AD07                                                                                                                                                                                                    

                                                                                                 Buclizine^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^                            R06AE01                                                                                                                                                                                                    

                                                                                                 Cyclizine^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^                            R06AE03                                                                                                                                                                                                    

                                                                                                 Chlorcyclizine^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^                       R06AE04                                                                                                                                                                                                    

                                                                                                 Meclizine (meclozine)^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^                R06AE05                                                                                                                                                                                                    

                                                                                                 Oxatomide^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^                            R06AE06                                                                                                                                                                                                    

                                                                                                 Buclizine, combinations                                                                     R06AE51                                                                                                                                                                                                    

                                                                                                 Meclizine, combinations                                                                     R06AE55                                                                                                                                                                                                    

                                                                                                 Homochlorcyclizine HCl (homoginin)^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^   R06AE91                                                                                                                                                                                                    

                                                                                                 Cyproheptadine^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^                       R06AX02                                                                                                                                                                                                    

                                                                                                 Phenindamine^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^                         R06AX04                                                                                                                                                                                                    

                                                                                                 Triprolidine^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^                         R06AX07                                                                                                                                                                                                    

                                                                                                 Mebhydrolin^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^                          R06AX15                                                                                                                                                                                                    

                                                                                                 Ketotifen^[†](#table-fn3-2040622319879602){ref-type="table-fn"}^                            R06AX17                                                                                                                                                                                                    

                                                                                                 Hydroxyzine^[\*\*](#table-fn2-2040622319879602){ref-type="table-fn"}^                       N05BB01                                                                                                                                                                                                    
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Chlordiazepoxide is classified as a benzodiazepine, and it is available in Taiwan by combining clidinium, anticholinergics or antacid as a single pill for gastrospasm or gastritis.

Hydroxyzine is classified as a first-generation antihistamine, but it can be used for sedation and anxiolysis.

Identical medications listed in the 2012 version of PIM-Taiwan criteria.

NSAID, nonsteroidal anti-inflammatory drug; PIM, potentially inappropriate medication; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant.

###### 

2018 version for potentially inappropriate medication use in persons aged ⩾65 years of age (PIM-Taiwan): drug--condition interactions that may cause the exacerbation of chronic diseases.

![](10.1177_2040622319879602-table2)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  System               Condition                                                    Medication classification                                                                                                   Concern
  -------------------- ------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Circulatory system   Heart failure                                                • Nonsteroidal anti-inflammatory drugs (non-COX-2 selective NSAIDs) (Table 3.1)                                             • Potential to promote fluid retention and exacerbate heart failure.

                                                                                    • Nonsteroidal anti-inflammatory drugs (COX-2 inhibitors) (Table 3.1.1)                                                     

                                                                                    • Nondihydropyridine calcium channel blockers (Table 3.2)                                                                   

                                                                                    • Thiazolidinediones (Table 3.3)                                                                                            

                       Syncope                                                      • Acetylcholinesterase Inhibitors (Table 3.4)                                                                               • Increases risk of orthostatic hypotension or bradycardia.

                                                                                    • Peripheral alpha-1 blockers (Table 3.5)                                                                                   

  Nervous system       Delirium, dementia, or cognitive impairment                  • Strongly anticholinergic drugs (Table 3.6)                                                                                • Avoid in older adults with or at high risk of delirium because of the potential to induce or worsen delirium.\
                                                                                                                                                                                                                • Avoid antipsychotics for behavioral problems of dementia or delirium unless nonpharmacological options (e.g. behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others.

                                                                                    • Antipsychotics (Table 3.7)                                                                                                

                       History of falls or fractures                                • Antipsychotics (Table 3.7)                                                                                                • May cause ataxia, impaired psychomotor function, additional falls; shorter-acting benzodiazepines are not safer than long-acting ones.\
                                                                                                                                                                                                                • If one of the drugs must be used, consider reducing the use of other CNS-active medications that increase risk of falls and fractures (i.e. anticonvulsants, opioid receptor agonists, antipsychotics, antidepressants, benzodiazepine receptor agonists, other sedatives and hypnotics) and implement other strategies to reduce fall risk.

                                                                                    • Benzodiazepines (Table 3.8)                                                                                               

                                                                                    • Nonbenzodiazepine hypnotics (Table 3.9)                                                                                   

                       Parkinson's disease                                          • Antipsychotics (except quetiapine and clozapine) (Table 3.7)                                                              • Dopamine-receptor antagonists with the potential to worsen Parkinsonian symptoms. Quetiapine, aripiprazole, clozapine appear to be less likely to precipitate the worsening of Parkinson's disease.

                                                                                    • Antiemetics (Table 3.6)                                                                                                   

  Digestive system     History of gastric or duodenal ulcers                        • Aspirin (\>325 mg/d)                                                                                                      • May exacerbate existing ulcers or cause new or additional ulcers.

                                                                                    • Nonsteroidal anti-inflammatory drugs (non-COX-2 selective NSAIDs) (Table 3.1)                                             

  Genitourinary        Chronic kidney disease (creatinine clearance \<30 ml/min)    • Nonsteroidal anti-inflammatory drugs (non-COX-2 selective NSAIDs and COX-2 inhibitors, oral and parenteral) (Table 3.1)   • May increase risk of acute kidney injury and further decline of renal function.

                       Lower urinary tract symptoms, benign prostatic hyperplasia   • Strongly anticholinergic drugs, except antimuscarinics for urinary incontinence (Table 3.6)                               • May decrease urinary flow and cause urinary retention.

  Respiratory system   Bronchial asthma, chronic obstructive pulmonary disease      • Nonselective beta-blockers (Table 3.10)                                                                                   • May worsen respiratory symptoms.
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CNS, central nervous system; NSAID, nonsteroidal anti-inflammatory drug; PIM, potentially inappropriate medication.

###### 

Individual medication list for medication classes in [Table 2](#table2-2040622319879602){ref-type="table"} for drug--condition interactions that may cause the exacerbation of chronic diseases.
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  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Medication classification                                               Drugs                               ATC code   Medication classification                         Drugs                         ATC code
  ----------------------------------------------------------------------- ----------------------------------- ---------- ------------------------------------------------- ----------------------------- ----------
  3.1 Nonsteroidal anti-inflammatory drugs (non-COX-2 selective NSAIDs)   Indomethacin                        M01AB01    3.3 Thiazolidinediones                            Pioglitazone                  A10BG03

                                                                          Sulindac                            M01AB02                                                      Rosiglitazone                 A10BG02

                                                                          Tolmetin                            M01AB03                                                                                    

                                                                          Diclofenac                          M01AB05    3.4 Acetylcholinesterase Inhibitors               Donepezil                     N06DA02

                                                                          Alclofenac                          M01AB06                                                      Rivastigmine                  N06DA03

                                                                          Etodolac                            M01AB08                                                      Galantamine                   N06DA04

                                                                          Acemetacin                          M01AB11                                                                                    

                                                                          Ketorolac                           M01AB15    3.5 Peripheral alpha-1 blockers                   Doxazosin                     C02CA04

                                                                          Aceclofenac                         M01AB16                                                      Prazosin                      C02CA01

                                                                          Piroxicam                           M01AC01                                                      Terazosin                     G04CA03

                                                                          Tenoxicam                           M01AC02                                                                                    

                                                                          Meloxicam                           M01AC06    3.6 Strongly anticholinergic drugs\               Flavoxate                     G04BD02
                                                                                                                         (antimuscarinics for urinary incontinence)                                      

                                                                          Ibuprofen                           M01AE01                                                      Oxybutynin                    G04BD04

                                                                          Naproxen                            M01AE02                                                      Solifenacin                   G04BD08

                                                                          Ketoprofen                          M01AE03                                                      Tolterodine                   G04BD07

                                                                          Fenoprofen                          M01AE04                                                      Trospium                      G04BD09

                                                                          Fenbufen                            M01AE05                                                                                    

                                                                          Flurbiprofen                        M01AE09    3.6 Strongly anticholinergic drugs\               Brompheniramine               R06AB01
                                                                                                                         (antihistamines)                                                                

                                                                          Tiaprofenic acid                    M01AE11                                                      Carbinoxamine                 R06AA08

                                                                          Mefenamic acid                      M01AG01                                                      Chlorpheniramine              R06AB04

                                                                          Flufenamic acid                     M01AG03                                                      Clemastine                    R06AA04

                                                                          Meclofenamic acid                   M01AG04                                                      Cyproheptadine                R06AX02

                                                                          Nabumetone                          M01AX01                                                      Dexchlorpheniramine           R06AB02

                                                                          Niflumic acid                       M01AX02                                                      Dimenhydrinate                R06AA02

                                                                          Benzydamine                         M01AX07                                                      Diphenhydramine (oral)        R06AA02

                                                                          Nimesulide                          M01AX17                                                      Doxylamine                    R06AA09

                                                                                                                                                                           Hydroxyzine                   N05BB01

  3.1 Nonsteroidal anti-inflammatory drugs (COX-2 selective NSAIDs)       Celecoxib                           M01AH01                                                      Meclizine                     R06AE05

                                                                          Etoricoxib                          M01AH05                                                      Triprolidine                  R06AX07

                                                                                                                                                                                                         

  3.2 Nondihydropyridine Calcium Channel Blockers                         Diltiazem                           C08DB01    3.6 Strongly anticholinergic drugs\               Trihexyphenidyl (benzhexol)   N04AA01
                                                                                                                         (antiparkinsonian agents)                                                       

                                                                          Verapamil                           C08DA01                                                      Biperiden                     N04AA02

  3.6 Strongly anticholinergic drugs (skeletal muscle relaxants)          Cyclobenzaprine                     M03BX08    3.7 Antipsychotics, chronic and as needed use\    Chlorpromazine                N05AA01
                                                                                                                         antipsychotics, first-generation (conventional)                                 

                                                                          Orphenadrine                        M03BC01                                                      Levomepromazine               N05AA02

                                                                                                                                                                           Fluphenazine                  N05AB02

  3.6 Strongly anticholinergic drugs (antidepressants)                    Amitriptyline                       N06AA09                                                      Perphenazine                  N05AB03

                                                                          Clomipramine                        N06AA04                                                      Trifluoperazine               N05AB06

                                                                          Doxepin (\>6 mg)                    N06AA12                                                      Thioridazine                  N05AC02

                                                                          Imipramine                          N06AA02                                                      Haloperidol                   N05AD01

                                                                          Paroxetine                          N06AB05                                                      Flupentixol                   N05AF01

                                                                                                                                                                           Chlorprothixene               N05AF03

  3.6 Strongly anticholinergic drugs (antipsychotics)                     Chlorpromazine                      N05AA01                                                      Pimozide                      N05AG02

                                                                          Clozapine                           N05AH02                                                      Loxapine                      N05AH01

                                                                          Loxapine                            N05AH01                                                      Sulpiride                     N05AL01

                                                                          Olanzapine                          N05AH03    3.7 Antipsychotics, chronic and as needed use\    Ziprasidone                   N05AE04
                                                                                                                         antipsychotics, second-generation (atypical)                                    

                                                                          Perphenazine                        N05AB03                                                      Lurasidone                    N05AE05

                                                                          Thioridazine                        N05AC02                                                      Clozapine                     N05AH02

                                                                          Trifluoperazine                     N05AB06                                                      Olanzapine                    N05AH03

                                                                                                                                                                           Quetiapine                    N05AH04

  3.6 Strongly anticholinergic drugs (antiarrhythmic)                     Disopyramide                        C01BA03                                                      Amisulpride                   N05AL05

                                                                                                                                                                           Risperidone                   N05AX08

  3.6 Strongly anticholinergic drugs (antispasmodics)                     Atropine (excludes ophthalmic)      A03BA01                                                      Zotepine                      N05AX11

                                                                          Belladonna alkaloids                A03BA04                                                      Aripiprazole                  N05AX12

                                                                          Clidinium- chlordiazepoxide         A03CA02                                                      Paliperidone                  N05AX13

                                                                          Dicyclomine                         A03AA07                                                                                    

                                                                          Hyoscyamine                         A03BA03    3.8 Nonselective beta-blocker                     Alprenolol                    C07AA01

                                                                          Propantheline                       A03AB05                                                      Carteolol                     C07AA15

                                                                          Scopolamine (excludes ophthalmic)   A04AD01                                                      Pindolol                      C07AA03

                                                                                                                                                                           Sotalol                       C07AA07

  3.6 Strongly anticholinergic drugs (antiemetics)                        Prochlorperazine                    N05AB04                                                                                    

                                                                          Promethazine                        R06AD02    3.9 Nonbenzodiazepine hypnotics                   Zopiclone                     N025CF01

                                                                                                                                                                           Zolpidem                      N025CF02

                                                                                                                                                                           Zaleplon                      N025CF03

                                                                                                                                                                           Eszopiclone                   N025CF04

  3.10 Benzodiazepines                                                    Clonazepam                          N03AE01    3.10 Benzodiazepines                              Nordazepam                    N05BA16

                                                                          Diazepam                            N05BA01                                                      Fludiazepam                   N05BA17

                                                                          Chlordiazepoxide                    N05BA02                                                      Oxazolam                      N05BA

                                                                          Medazepam                           N05BA03                                                      Flurazepam                    N05CD01

                                                                          Oxazepam                            N05BA04                                                      Nitrazepam                    N05CD02

                                                                          Lorazepam                           N05BA06                                                      Flunitrazepam                 N05CD03

                                                                          Bromazepam                          N05BA08                                                      Estazolam                     N05CD04

                                                                          Clobazam                            N05BA09                                                      Triazolam                     N05CD05

                                                                          Prazepam                            N05BA11                                                      Midazolam                     N05CD08

                                                                          Alprazolam                          N05BA12                                                      Brotizolam                    N05CD09
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NSAID, nonsteroidal anti-inflammatory drug.

###### 

Medications or criteria removed since the 2012 PIM-Taiwan criteria.
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  Independent of diseases               Considering diseases
  ------------------------------------- ---------------------------------------------------------------------------------
  • Belladonna alkaloid (A03BA/A03BB)   • Blood clotting disorders or receiving anticoagulant therapy, entire criterion
  • Hyoscyamine products (A03BA03)      • Chronic constipation, entire criterion
  • Ticlopidine (B01AC05)               • Glaucoma, entire criterion
  • Methyldopa (C02AB01)                • Sleep apnea syndrome, entire criterion
  • Reserpine (C02AA02)                 • Urinary incontinence, entire criterion
  • Phenylbutazone (M01AA01)            • Chronic obstructive pulmonary disease, benzodiazepine
  • **Muscle relaxants**                • Cognitive impairment, dementia- benzodiazepine
  • Baclofen (M03BX01)                  
  • Carisoprodol (M03BA02)              
  • Chlormezanone (M03BB02)             
  • Chlorphenesin carbamate (M03)       
  • Chlorzoxazone (M03BB03)             
  • Cyclobenzaprine (M03BX08)           
  • Dantrolene (M03CA01)                
  • Methocarbamol (M03BA03)             
  • Orphenadrine (M03BC01)              
  • Phenprobamate (M03BA01)             
  • Pridinol (M03BX03)                  
  • Tizanidine (M03BX02)                
  • Tolperisone (M03BX04)               
  • Pethidine (N02AB02)                 
  • Propoxyphene (N02AC04)              
  • Potassium clorazepate (N05BA05)     
  • Meprobamate (N05BC01)               
  • Amobarbital (N05CA02)               
  • Pentobarbital (N05CA01)             
  • Secobarbital (N05CA06)              
  • Dosulepin (N06AA16)^\*^             
  • Alimemazine (R06AD01)^\*^           
  • Azatadine (R06AX09)^\*^             
  • Chlorphenoxamine (R06AA06)^\*^      
  • Mepyramine (R06AC01)^\*^            
  • Pheniramine (R06AB05)^\*^           
  • Tripelennamine (R06AC04)^\*^        

PIM, potentially inappropriate medication, 2012 PIM-Taiwan criteria.^[@bibr29-2040622319879602]^

For drug--disease interactions, the entire criterion was removed, including blood clotting disorders or anticoagulant therapy, chronic constipation, glaucoma, sleep apnea syndrome, and urinary incontinence. Statements were removed for benzodiazepines for patients with chronic obstructive pulmonary disease and benzodiazepines for patients with cognitive impairment or dementia.

ICC estimates for PIMs to be avoided generally were 0.634 (95% confidence interval 0.540--0.716, *p* \< 0.001) and 0.557 (95% confidence interval 0.444--0.657, *p* \< 0.001) in rounds one and two of the Delphi method, respectively ([Table 5](#table5-2040622319879602){ref-type="table"}). The ICC estimates for PIMs considering chronic disease were 0.866 (95% confidence interval 0.760--0.939, *p* \< 0.001) and 0.775 (95% confidence interval 0.599--0.898, **p** \< 0.001) in rounds one and two of the Delphi method, respectively. This result indicated that there was moderate or good reliability in experts' measurements for each PIM statement.

###### 

Summary of interrater reliability statistics for medications considered to be potentially inappropriate.

![](10.1177_2040622319879602-table5)

                                     Round 1   Round 2                                                          
  ---------------------------------- --------- -------------- --------- ------ ------- -------------- --------- ------
  PIM to be avoided generally        0.634     0.540--0.716   \<0.001   2.73   0.557   0.444--0.657   \<0.001   2.26
  PIM considering chronic diseases   0.866     0.760--0.939   \<0.001   7.45   0.775   0.599--0.898   \<0.001   4.45

Intraclass correlation coefficients using mean-rating (*k* = 24), consistency, two-way mixed effects model (0.75 \> ICC \> 0.5 describes moderate reliability, 0.9 \> ICC \> 0.75 describes good reliability).

CI, confidence interval; PIM, potentially inappropriate medication.

Discussion {#section11-2040622319879602}
==========

Explicit criteria with a listing of potentially inappropriate criteria have been established since 1991. These criteria have been applied to discourage the use of high-risk drugs among older people and have been used as indicators for prescription quality. The first version of the PIM-Taiwan criteria was published in 2012. Our methodology has been used as a reference to develop regional PIM lists because the literature review processes were dynamic and complex. After the PIM-Taiwan criteria were published, more than half of the regional PIM criteria were established using prior PIM lists.

Without adding new areas to our PIM criteria, the 2018 version of the PIM criteria only has two categories of PIMs, including PIMs that are generally avoided ([Table 1](#table1-2040622319879602){ref-type="table"}) and those considered potentially inappropriate in certain chronic diseases ([Table 2](#table2-2040622319879602){ref-type="table"}). After the PIM-Taiwan criteria were updated, many medication classes and drugs that are newly available in Taiwan have been added to the 2018 version. In contrast, some medications and drug--disease interaction statements were removed ([Table 4](#table4-2040622319879602){ref-type="table"}). The user-friendly characteristics of the statements were retained, including alternative therapies or suggestions for PIMs in [Table 1](#table1-2040622319879602){ref-type="table"}, and the concern and the ATC code for each PIM.

The experts who participated in the establishment of the most frequently published PIM criteria were geriatricians, psychiatrists, and clinical pharmacists. In this study, we invited many experts from other specialties including gastroenterology, cardiology, pulmonary medicine, neurology, and urology, to reflect the multidisciplinary perspectives. With a multidisciplinary approach, the rating of some PIMs in the preliminary list can be more heterogeneous, particularly for medications commonly prescribed in certain specialties. In [Table 1](#table1-2040622319879602){ref-type="table"}, the quetiapine and insulin sliding scale was not considered to be potentially inappropriate. Quetiapine has a less negative influence on mortality than do other antipsychotics. In addition, the majority of its adverse drug events were preventable. Although we did not regard it as a PIM in the PIM criteria, physicians still need to monitor its adverse events and avoid long-term use. For the sole use of sliding scale insulin, we could not conclude from current systemic reviews that using other strategies can reduce hyperglycemia and prevent hypoglycemia. Therefore, we did not include this statement as PIM. In [Table 2](#table2-2040622319879602){ref-type="table"}, all experts agreed that these medication classes were potentially inappropriate in their corresponding chronic comorbidities.

After we published our strategy to establish a new country- or region-specific PIM criteria,^[@bibr29-2040622319879602]^ several sets of criteria were established using a similar methodology. If we use all the newly published sets of criteria to establish our preliminary lists, we find that some of the PIMs are duplicated, because they may be derived from other criteria, such as the Beers criteria. Therefore, we only selected those established based on the results of a literature review and a subsequently modified Delphi method. As a result of this strategy, in [Table 1](#table1-2040622319879602){ref-type="table"}, two classes of medications (barbiturates and muscle relaxants) that were regarded as PIMs in the first version of our criteria were removed. In [Table 2](#table2-2040622319879602){ref-type="table"}, five chronic diseases (blood clotting disorders or anticoagulant therapy, chronic constipation, glaucoma, sleep apnea syndrome, and urinary incontinence) were removed, because these diseases were not restricted to older adults. These disease--medication interactions should be considered among the general population without regard to age.

Polypharmacy has been shown to be associated with adverse outcomes, high healthcare costs, and poor quality of life. The avoidance of potentially inappropriate medication is an important strategy to prevent adverse drug events and to deprescribe for older adults. In the systemic review, deprescribing seems to be an effective strategy to reduce mortality in nonrandomized studies. However, when studies aim to investigate the effect of implicit and explicit tools on the outcome of reducing PIMs, the benefit of interventions was not clear. When using implicit criteria, pharmacists or other clinicians need more knowledge and clinical experiences to identify target medications for deprescribing. In addition, clinicians may identify different targets for deprescribing without a clear reference. In contrast, the use of explicit criteria is straightforward and simple. Therefore, PIM criteria can be an important tool to reduce PIM-related adverse events. After our PIM-Taiwan criteria are updated, more PIMs could be identified.^[@bibr22-2040622319879602]^ However, the number of individual drugs and statements increased when PIM lists were updated, and it would be a barrier for clinicians to apply these tools efficiently in clinical practice. With the assistance of e-prescribing or computerized physician order entry systems, the positive effect of reduced PIMs has been demonstrated in several studies.^[@bibr30-2040622319879602]^

The first disadvantage of this tool was that PIMs were derived from existing criteria, and new findings from recent clinical trials were not fully reviewed. Our criteria only listed drugs to be avoided and not those that should be initiated among older adults. Second, for ease of application in clinical practice, we did not use the complex classification system adopted by the 2015 version of the Beers criteria including PIMs to be used with caution, drug--drug interactions, and dose consideration with varying levels of kidney function in older adults. Third, all medications listed in these criteria were available in the medication database from the National Health Insurance Administration in Taiwan. Therefore, the criteria should be modified before applying them in other countries.

Conclusion {#section12-2040622319879602}
==========

In conclusion, a 2018 version of the PIM-Taiwan criteria was developed through a systemic method that could be replicated by other groups. Several important modifications were made to maintain the relevance and usefulness of the criteria. Its user-friendly characteristics will help clinicians to reduce polypharmacy and PIMs among older patients.
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